Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults.
Identifieur interne : 002660 ( Main/Exploration ); précédent : 002659; suivant : 002661Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults.
Auteurs : Terry Nolan [Australie] ; Miguel O'Ryan [Chili] ; James Wassil [États-Unis] ; Véronique Abitbol [France] ; Peter Dull [États-Unis]Source :
- Vaccine [ 1873-2518 ] ; 2015.
Descripteurs français
- KwdFr :
- Activité bactéricide du sang, Adolescent, Anticorps antibactériens (sang), Humains, Infections à méningocoques (), Infections à méningocoques (épidémiologie), Jeune adulte, Neisseria meningitidis sérogroupe B (immunologie), Santé mondiale, Vaccins antiméningococciques (administration et posologie), Vaccins antiméningococciques (effets indésirables), Vaccins antiméningococciques (immunologie).
- MESH :
- administration et posologie : Vaccins antiméningococciques.
- effets indésirables : Vaccins antiméningococciques.
- immunologie : Neisseria meningitidis sérogroupe B, Vaccins antiméningococciques.
- sang : Anticorps antibactériens.
- épidémiologie : Infections à méningocoques.
- Activité bactéricide du sang, Adolescent, Humains, Infections à méningocoques, Jeune adulte, Santé mondiale.
English descriptors
- KwdEn :
- Adolescent, Antibodies, Bacterial (blood), Blood Bactericidal Activity, Global Health, Humans, Meningococcal Infections (epidemiology), Meningococcal Infections (prevention & control), Meningococcal Vaccines (administration & dosage), Meningococcal Vaccines (adverse effects), Meningococcal Vaccines (immunology), Neisseria meningitidis, Serogroup B (immunology), Young Adult.
- MESH :
- chemical , administration & dosage : Meningococcal Vaccines.
- chemical , adverse effects : Meningococcal Vaccines.
- chemical , blood : Antibodies, Bacterial.
- epidemiology : Meningococcal Infections.
- chemical , immunology : Meningococcal Vaccines, Neisseria meningitidis, Serogroup B.
- prevention & control : Meningococcal Infections.
- Adolescent, Blood Bactericidal Activity, Global Health, Humans, Young Adult.
Abstract
Vaccination programs employing capsular-based meningococcal vaccines have proved successful in a variety of settings globally since first introduced over 40 years ago. Similar successes have been demonstrated using meningococcal vaccines for use against serogroup B (MenB) outbreak strains but the diversity of MenB strains has limited vaccine use outside targeted geographic regions. MenB continues to be a significant cause of outbreaks in adolescents and young adults, as recently demonstrated in university settings in the US (Princeton, New Jersey and Santa Barbara, California) and has the potential for hyperendemic disease levels such as currently experienced in Québec and the United Kingdom. In adolescents, increased endemic disease rates and outbreak potential are likely associated with social behaviors putting individuals at risk for carriage acquisition and may explain regional and temporal variations in epidemiology. A protein-based, multi-component MenB vaccine (4CMenB) is currently licensed for use in 37 countries including EU/EEA countries, Australia, Canada, Chile, Colombia, Uruguay, and the US. In this article we review the most recent clinical trial data with 4CMenB with a focus on adolescents and young adults. The vaccine appears to have an acceptable safety profile and is well-tolerated in adolescents and young adults while providing robust, persistent levels of bactericidal antibodies considered protective for each of the four antigenic components of the vaccine. With the recent availability of this vaccine, health care providers have the first comprehensive opportunity to control meningococcal disease, a highly disruptive public health problem with a disproportionate impact on adolescents and young adults.
DOI: 10.1016/j.vaccine.2015.06.011
PubMed: 26187261
Affiliations:
- Australie, Chili, France, États-Unis
- Massachusetts, Victoria (État), Île-de-France
- Melbourne, Suresnes
- Université de Melbourne
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002A53
- to stream PubMed, to step Curation: 002983
- to stream PubMed, to step Checkpoint: 002983
- to stream Ncbi, to step Merge: 002850
- to stream Ncbi, to step Curation: 002850
- to stream Ncbi, to step Checkpoint: 002850
- to stream Main, to step Merge: 002660
- to stream Main, to step Curation: 002660
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults.</title><author><name sortKey="Nolan, Terry" sort="Nolan, Terry" uniqKey="Nolan T" first="Terry" last="Nolan">Terry Nolan</name><affiliation wicri:level="4"><nlm:affiliation>Melbourne School of Population and Global Health, The University of Melbourne, and Murdoch Children's Research Institute, Victoria 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Melbourne School of Population and Global Health, The University of Melbourne, and Murdoch Children's Research Institute, Victoria 3010</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="O Ryan, Miguel" sort="O Ryan, Miguel" uniqKey="O Ryan M" first="Miguel" last="O'Ryan">Miguel O'Ryan</name><affiliation wicri:level="1"><nlm:affiliation>Programa de Microbiología y Micología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Avda Independencia 1027, Santiago, Chile.</nlm:affiliation><country xml:lang="fr">Chili</country><wicri:regionArea>Programa de Microbiología y Micología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Avda Independencia 1027, Santiago</wicri:regionArea><wicri:noRegion>Santiago</wicri:noRegion></affiliation></author><author><name sortKey="Wassil, James" sort="Wassil, James" uniqKey="Wassil J" first="James" last="Wassil">James Wassil</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Vaccines and Diagnostics Inc., 350 Massachusetts Avenue, Cambridge, MA 02139, USA. Electronic address: jimwassil@yahoo.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Vaccines and Diagnostics Inc., 350 Massachusetts Avenue, Cambridge, MA 02139</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Abitbol, Veronique" sort="Abitbol, Veronique" uniqKey="Abitbol V" first="Véronique" last="Abitbol">Véronique Abitbol</name><affiliation wicri:level="3"><nlm:affiliation>Novartis Vaccines and Diagnostics, Inc., S.A.S.10, Rue Chevreul, F-92150 Suresnes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Novartis Vaccines and Diagnostics, Inc., S.A.S.10, Rue Chevreul, F-92150 Suresnes</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Suresnes</settlement></placeName></affiliation></author><author><name sortKey="Dull, Peter" sort="Dull, Peter" uniqKey="Dull P" first="Peter" last="Dull">Peter Dull</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Vaccines and Diagnostics Inc., 350 Massachusetts Avenue, Cambridge, MA 02139, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Vaccines and Diagnostics Inc., 350 Massachusetts Avenue, Cambridge, MA 02139</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26187261</idno><idno type="pmid">26187261</idno><idno type="doi">10.1016/j.vaccine.2015.06.011</idno><idno type="wicri:Area/PubMed/Corpus">002A53</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002A53</idno><idno type="wicri:Area/PubMed/Curation">002983</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002983</idno><idno type="wicri:Area/PubMed/Checkpoint">002983</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002983</idno><idno type="wicri:Area/Ncbi/Merge">002850</idno><idno type="wicri:Area/Ncbi/Curation">002850</idno><idno type="wicri:Area/Ncbi/Checkpoint">002850</idno><idno type="wicri:Area/Main/Merge">002660</idno><idno type="wicri:Area/Main/Curation">002660</idno><idno type="wicri:Area/Main/Exploration">002660</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults.</title><author><name sortKey="Nolan, Terry" sort="Nolan, Terry" uniqKey="Nolan T" first="Terry" last="Nolan">Terry Nolan</name><affiliation wicri:level="4"><nlm:affiliation>Melbourne School of Population and Global Health, The University of Melbourne, and Murdoch Children's Research Institute, Victoria 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Melbourne School of Population and Global Health, The University of Melbourne, and Murdoch Children's Research Institute, Victoria 3010</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="O Ryan, Miguel" sort="O Ryan, Miguel" uniqKey="O Ryan M" first="Miguel" last="O'Ryan">Miguel O'Ryan</name><affiliation wicri:level="1"><nlm:affiliation>Programa de Microbiología y Micología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Avda Independencia 1027, Santiago, Chile.</nlm:affiliation><country xml:lang="fr">Chili</country><wicri:regionArea>Programa de Microbiología y Micología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Avda Independencia 1027, Santiago</wicri:regionArea><wicri:noRegion>Santiago</wicri:noRegion></affiliation></author><author><name sortKey="Wassil, James" sort="Wassil, James" uniqKey="Wassil J" first="James" last="Wassil">James Wassil</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Vaccines and Diagnostics Inc., 350 Massachusetts Avenue, Cambridge, MA 02139, USA. Electronic address: jimwassil@yahoo.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Vaccines and Diagnostics Inc., 350 Massachusetts Avenue, Cambridge, MA 02139</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Abitbol, Veronique" sort="Abitbol, Veronique" uniqKey="Abitbol V" first="Véronique" last="Abitbol">Véronique Abitbol</name><affiliation wicri:level="3"><nlm:affiliation>Novartis Vaccines and Diagnostics, Inc., S.A.S.10, Rue Chevreul, F-92150 Suresnes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Novartis Vaccines and Diagnostics, Inc., S.A.S.10, Rue Chevreul, F-92150 Suresnes</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Suresnes</settlement></placeName></affiliation></author><author><name sortKey="Dull, Peter" sort="Dull, Peter" uniqKey="Dull P" first="Peter" last="Dull">Peter Dull</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Vaccines and Diagnostics Inc., 350 Massachusetts Avenue, Cambridge, MA 02139, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Vaccines and Diagnostics Inc., 350 Massachusetts Avenue, Cambridge, MA 02139</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Antibodies, Bacterial (blood)</term><term>Blood Bactericidal Activity</term><term>Global Health</term><term>Humans</term><term>Meningococcal Infections (epidemiology)</term><term>Meningococcal Infections (prevention & control)</term><term>Meningococcal Vaccines (administration & dosage)</term><term>Meningococcal Vaccines (adverse effects)</term><term>Meningococcal Vaccines (immunology)</term><term>Neisseria meningitidis, Serogroup B (immunology)</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Activité bactéricide du sang</term><term>Adolescent</term><term>Anticorps antibactériens (sang)</term><term>Humains</term><term>Infections à méningocoques ()</term><term>Infections à méningocoques (épidémiologie)</term><term>Jeune adulte</term><term>Neisseria meningitidis sérogroupe B (immunologie)</term><term>Santé mondiale</term><term>Vaccins antiméningococciques (administration et posologie)</term><term>Vaccins antiméningococciques (effets indésirables)</term><term>Vaccins antiméningococciques (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Meningococcal Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Meningococcal Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Bacterial</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiméningococciques</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antiméningococciques</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Meningococcal Infections</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Neisseria meningitidis sérogroupe B</term><term>Vaccins antiméningococciques</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Meningococcal Vaccines</term><term>Neisseria meningitidis, Serogroup B</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Meningococcal Infections</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antibactériens</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à méningocoques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Blood Bactericidal Activity</term><term>Global Health</term><term>Humans</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Activité bactéricide du sang</term><term>Adolescent</term><term>Humains</term><term>Infections à méningocoques</term><term>Jeune adulte</term><term>Santé mondiale</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Vaccination programs employing capsular-based meningococcal vaccines have proved successful in a variety of settings globally since first introduced over 40 years ago. Similar successes have been demonstrated using meningococcal vaccines for use against serogroup B (MenB) outbreak strains but the diversity of MenB strains has limited vaccine use outside targeted geographic regions. MenB continues to be a significant cause of outbreaks in adolescents and young adults, as recently demonstrated in university settings in the US (Princeton, New Jersey and Santa Barbara, California) and has the potential for hyperendemic disease levels such as currently experienced in Québec and the United Kingdom. In adolescents, increased endemic disease rates and outbreak potential are likely associated with social behaviors putting individuals at risk for carriage acquisition and may explain regional and temporal variations in epidemiology. A protein-based, multi-component MenB vaccine (4CMenB) is currently licensed for use in 37 countries including EU/EEA countries, Australia, Canada, Chile, Colombia, Uruguay, and the US. In this article we review the most recent clinical trial data with 4CMenB with a focus on adolescents and young adults. The vaccine appears to have an acceptable safety profile and is well-tolerated in adolescents and young adults while providing robust, persistent levels of bactericidal antibodies considered protective for each of the four antigenic components of the vaccine. With the recent availability of this vaccine, health care providers have the first comprehensive opportunity to control meningococcal disease, a highly disruptive public health problem with a disproportionate impact on adolescents and young adults.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Chili</li><li>France</li><li>États-Unis</li></country><region><li>Massachusetts</li><li>Victoria (État)</li><li>Île-de-France</li></region><settlement><li>Melbourne</li><li>Suresnes</li></settlement><orgName><li>Université de Melbourne</li></orgName></list><tree><country name="Australie"><region name="Victoria (État)"><name sortKey="Nolan, Terry" sort="Nolan, Terry" uniqKey="Nolan T" first="Terry" last="Nolan">Terry Nolan</name></region></country><country name="Chili"><noRegion><name sortKey="O Ryan, Miguel" sort="O Ryan, Miguel" uniqKey="O Ryan M" first="Miguel" last="O'Ryan">Miguel O'Ryan</name></noRegion></country><country name="États-Unis"><region name="Massachusetts"><name sortKey="Wassil, James" sort="Wassil, James" uniqKey="Wassil J" first="James" last="Wassil">James Wassil</name></region><name sortKey="Dull, Peter" sort="Dull, Peter" uniqKey="Dull P" first="Peter" last="Dull">Peter Dull</name></country><country name="France"><region name="Île-de-France"><name sortKey="Abitbol, Veronique" sort="Abitbol, Veronique" uniqKey="Abitbol V" first="Véronique" last="Abitbol">Véronique Abitbol</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002660 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002660 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26187261
|texte= Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26187261" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |